Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris (NCT03662685) | Clinical Trial Compass
TerminatedPhase 1
Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris
Stopped: Closing of the Goeckerman program at UCSF and loss of funding, PI left UCSF
United States4 participantsStarted 2018-08-01
Plain-language summary
This study examines the effect of Goeckerman therapy (a combination of phototherapy and topical crude coal tar), crude coal tar alone, and phototherapy alone on the immunologic and genetic environment within psoriatic skin lesions.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male or female ≥ 18 years of age at enrollment.
✓. Documentation of predominately moderate to severe plaque psoriasis for at least 6 months prior to enrollment.
✓. Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
✓. Subject is considered a candidate for phototherapy or systemic therapy
✓. Body Surface Area (BSA) ≥ 5%.
✓. Physical exam within clinically acceptable limits.
Exclusion criteria
✕. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
✕. Subject has predominantly non-plaque form of psoriasis.
✕. Subject has drug-induced psoriasis.
✕. Subject with current, or a history of, severe psoriatic arthritis well controlled on current therapy.
✕. Patient has absolute or relative contraindication to phototherapy, including photosensitizing disorders.
✕. Evidence of abnormality of any immune cell population from a drug-induced or genetic cause.
✕. Known HIV positive status.
What they're measuring
1
Number of differentially expressed immune cell populations